% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Heck:21893,
      author       = {Heck, A. and Tielker, D. and Ernst, J.F. and Freudl, R. and
                      Bott, M. and Oldiges, M. and Wiechert, W. and Pietruszka, J.
                      and Wilhelm, S. and Rosenau, F. and Drepper, T. and Jaeger,
                      K.-E.},
      title        = {{E}xpressionsoptimierung in {M}ikroorganismen},
      journal      = {Biospektrum},
      volume       = {18},
      issn         = {0947-0867},
      address      = {Heidelberg},
      publisher    = {Spektrum},
      reportid     = {PreJuSER-21893},
      pages        = {449 - 451},
      year         = {2012},
      note         = {Record converted from VDB: 12.11.2012},
      abstract     = {Vitamin D receptor (VDR) expression has been shown to be
                      upregulated in several tumors and is supposed to represent
                      an important endogenous response to tumor progression. To
                      investigate the role of the VDR gene and its influence on
                      25(OH)D(3) and 1,25(OH)(2)D(3) plasma levels in thyroid
                      carcinoma, we analyzed four VDR polymorphisms in patients
                      and healthy controls (HC).Patients with thyroid carcinoma (n
                      = 172) (n = 132 for papillary and n = 40 for follicular) and
                      HC (n = 321) were genotyped for the ApaI (rs7975232), TaqI
                      (rs731236), BsmI (rs1544410), and FokI (rs10735810)
                      polymorphisms within the VDR gene and correlated with
                      25(OH)D(3) and 1,25(OH)(2)D(3) plasma levels.The genotypes
                      AA of the ApaI (rs7975232) and FF of the FokI (rs10735810)
                      polymorphisms were significantly less frequent $(12.5\%$ vs.
                      $35.2\%$ and $25\%$ vs. $42.1\%,$ respectively, both
                      corrected p [p(c)] = 0.04) in patients with follicular
                      thyroid cancer (FTC) than in HC. Additionally, the
                      haplotypes, Ta $(57.5\%$ vs. $41.4\%;$ p(c) = 0.0207), af
                      $(24.6\%$ vs. $14.3\%;$ p(c) = 0.0116), Tab $(51.1\%$ vs.
                      $36.8\%;$ p(c) = 0.0495), and Tabf $(18.7\%$ vs. $13.6\%;$
                      p(c) = 0.0240) were more frequent, whereas the haplotypes AF
                      $(17.1\%$ vs. $37.2\%;$ p(c) = 0.0008), BF $(11.4\%$ vs.
                      $31.9\%;$ p(c) = 0.012), tF $(7.9\%$ vs. $25.5\%;$ p(c) =
                      0.0016), and tABF $(7.6\%$ vs. $23\%;$ p(c) = 0.0115) were
                      less frequent in the FTC patients compared to HC. Neither
                      genotype nor haplotype frequencies differed between patients
                      with papillary thyroid cancer (PTC) and HC. Further,
                      individuals with PTC and FTC had a significantly lower level
                      of circulating 1,25(OH)(2)D(3) compared to controls. In
                      contrast, no differences of the 25(OH)D(3) concentration
                      between patients and HC were observed. VDR polymorphisms
                      were not associated with 25(OH)D(3) and 1,25(OH)(2)D(3)
                      plasma levels.Lower circulating levels of 1,25(OH)(2)D(3)
                      are observed in patients with differentiated thyroid
                      carcinoma. Further, while the alleles AA and FF of the ApaI
                      (rs7975232) and FokI (rs10735810) VDR polymorphisms and the
                      haplotype tABF confer to protection from follicular
                      carcinoma, the haplotype Tabf appeared to be associated with
                      an increased FTC risk. Since this is the first report
                      associating VDR polymorphisms with thyroid carcinoma, these
                      findings need to be confirmed in studies with larger numbers
                      of patients.},
      keywords     = {Autoantibodies: immunology / Calcifediol: metabolism /
                      Calcitriol: metabolism / Carcinoma, Papillary, Follicular:
                      genetics / Carcinoma, Papillary, Follicular: pathology /
                      Cell Differentiation / Female / Genotype / Haplotypes /
                      Humans / Male / Neutrophil Infiltration / Polymorphism,
                      Genetic: genetics / Receptors, Calcitriol: genetics /
                      Thyroid Gland: immunology / Thyroid Neoplasms: genetics /
                      Thyroid Neoplasms: pathology / Vitamin D: physiology /
                      Autoantibodies (NLM Chemicals) / Receptors, Calcitriol (NLM
                      Chemicals) / Vitamin D (NLM Chemicals) / Calcifediol (NLM
                      Chemicals) / Calcitriol (NLM Chemicals)},
      cin          = {IBT-2},
      ddc          = {570},
      cid          = {I:(DE-Juel1)VDB56},
      pnm          = {Biotechnologie},
      pid          = {G:(DE-Juel1)FUEK410},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:19499989},
      doi          = {10.1007/s12268-012-0207-7},
      url          = {https://juser.fz-juelich.de/record/21893},
}